SARS-CoV-2
ChAdOx1
A modified chimpanzee adenovirus was chosen to deliver the vaccine
It can’t replicate in humans, causing ongoing infection, and has been shown to create a strong immune response from one dose in other vaccines
The coronavirus is so-called due to its spike proteins
Studies show that these are a good target for the vaccine
The genes which code for the spikes are identified
This genetic sequence is spliced with the ChAdOx1 construct, creating the vaccine
When the ChAdOx1 contruct infects human cells, they produce the spike protein, inducing an immune response
The immune system is now primed to attack a Covid-19 infection
Around 50,000 people are enrolled in combined phase 2/3 and phase 3 trials of the vaccine in the UK, US, South Africa and Brazil
The group said they may be able to present data from trials to regulators before the end of 2020
ChAdOx1
SARS-CoV-2
A modified chimpanzee adenovirus was chosen to deliver the vaccine
It can’t replicate in humans, causing ongoing infection, and has been shown to create a strong immune response from one dose in other vaccines
The coronavirus is so-called due to its spike proteins
Studies show that these are a good target for the vaccine
The genes which
code for the spikes
are identified
This genetic sequence is spliced with the ChAdOx1 construct, creating the vaccine
When the ChAdOx1 contruct infects human cells, they produce the spike protein, inducing an immune response
The immune system is now primed to attack a Covid-19 infection
Around 50,000 people are enrolled in combined phase 2/3 and phase 3 trials of the vaccine in the UK, US, South Africa and Brazil
The group said they may be able to present data from trials to regulators before the end of 2020